[Form 4] Iovance Biotherapeutics, Inc. Insider Trading Activity
Corleen M. Roche, Chief Financial Officer of Iovance Biotherapeutics (IOVA), reported equity awards dated 08/06/2025. The Form 4 discloses a grant of 300,000 stock options with a $2.58 exercise price and an expiration date listed as 08/06/2035, and 150,000 restricted stock units (RSUs), each representing a contingent right to one share of common stock. Both awards are held directly following the reported transactions. The awards vest only if the reporting person remains employed: one-third vests on the one-year anniversary of the grant and the remaining two-thirds vest in eight equal quarterly installments over the following two years. The form is signed by Corleen Roche on 08/08/2025.
Corleen M. Roche, Chief Financial Officer di Iovance Biotherapeutics (IOVA), ha segnalato attribuzioni di capitale datate 08/06/2025. Il Form 4 indica una concessione di 300,000 opzioni su azioni con prezzo di esercizio di $2.58 e data di scadenza 08/06/2035, e 150,000 unità azionarie vincolate (RSU), ciascuna rappresentante un diritto condizionato a una azione ordinaria. Entrambe le assegnazioni sono detenute direttamente dopo le operazioni riportate. Le assegnazioni maturano solo se la dichiarante rimane impiegata: un terzo matura al primo anniversario della concessione e i restanti due terzi maturano in otto rate trimestrali uguali nei due anni successivi. Il modulo è firmato da Corleen Roche il 08/08/2025.
Corleen M. Roche, directora financiera (Chief Financial Officer) de Iovance Biotherapeutics (IOVA), informó adjudicaciones de capital fechadas 08/06/2025. El Form 4 revela una concesión de 300,000 opciones sobre acciones con un precio de ejercicio de $2.58 y fecha de vencimiento 08/06/2035, y 150,000 unidades de acciones restringidas (RSU), cada una representando un derecho condicional a una acción común. Ambas adjudicaciones se mantienen en propiedad directa tras las transacciones reportadas. Las adjudicaciones solo se consolidan si la persona informante permanece empleada: un tercio se consolida en el primer aniversario de la concesión y los restantes dos tercios se consolidan en ocho cuotas trimestrales iguales durante los dos años siguientes. El formulario está firmado por Corleen Roche el 08/08/2025.
Iovance Biotherapeutics (IOVA)의 최고재무책임자(CFO) Corleen M. Roche가 08/06/2025자 자본 보상 내역을 보고했습니다. Form 4는 행사가 $2.58인 스톡옵션 300,000주의 부여와 만기일 08/06/2035, 그리고 제한부주식단위(RSU) 150,000주(각각 보통주 1주에 대한 조건부 권리)를 공개합니다. 두 보상 모두 보고된 거래 이후 직접 보유됩니다. 보상은 보고인이 계속 고용된 경우에만 확정됩니다: 1/3은 부여일로부터 1년 되는 날에 확정되고, 나머지 2/3은 이후 2년 동안 8회의 동일한 분기별 할부로 확정됩니다. 양식은 08/08/2025에 Corleen Roche가 서명했습니다.
Corleen M. Roche, directrice financière (Chief Financial Officer) d'Iovance Biotherapeutics (IOVA), a déclaré des attributions de capital datées 08/06/2025. Le Form 4 indique une attribution de 300,000 options sur actions avec un prix d'exercice de $2.58 et une date d'expiration au 08/06/2035, et 150,000 unités d'actions restreintes (RSU), chacune représentant un droit conditionnel à une action ordinaire. Les deux attributions sont détenues directement après les opérations déclarées. Les attributions ne deviennent acquises que si la personne déclarée reste employée : un tiers devient acquis à l'anniversaire d'un an de l'attribution et les deux tiers restants deviennent acquis en huit versements trimestriels égaux au cours des deux années suivantes. Le formulaire est signé par Corleen Roche le 08/08/2025.
Corleen M. Roche, Chief Financial Officer von Iovance Biotherapeutics (IOVA), meldete Aktienzuteilungen datiert 08/06/2025. Das Form 4 gibt eine Gewährung von 300,000 Aktienoptionen mit einem Ausübungspreis von $2.58 und einem Verfallsdatum am 08/06/2035 sowie 150,000 Restricted Stock Units (RSUs) an, wobei jede eine bedingte Anspruchsberechtigung auf eine Stammaktie darstellt. Beide Zuteilungen werden nach den gemeldeten Transaktionen direkt gehalten. Die Zuteilungen erfolgen nur, falls die meldepflichtige Person weiter beschäftigt bleibt: ein Drittel wird am einjährigen Jahrestag der Gewährung fällig und die verbleibenden zwei Drittel in acht gleichen vierteljährlichen Tranchen über die folgenden zwei Jahre. Das Formular ist am 08/08/2025 von Corleen Roche unterzeichnet.
- 300,000 stock options granted at a $2.58 exercise price (direct beneficial ownership)
- 150,000 RSUs granted, each representing a contingent right to one share of common stock
- Clear vesting schedule: one-third at one-year anniversary, remaining two-thirds in eight equal quarterly installments over the following two years
- Awards are contingent on continued employment (vesting occurs only if the reporting person remains employed)
- 450,000 underlying shares in total (300,000 options + 150,000 RSUs) could be issued upon exercise/settlement
Insights
TL;DR Routine CFO equity grants: 300,000 options and 150,000 RSUs—limited immediate financial disclosure beyond grant terms.
The Form 4 documents standard long-term incentive awards to CFO Corleen Roche on 08/06/2025: 300,000 stock options at a $2.58 strike with an 08/06/2035 expiration and 150,000 RSUs convertible to common shares. Both holdings are reported as direct beneficial ownership following the transaction. The disclosed vesting schedule (one-third at one year; remainder in eight quarterly installments over two years) ties realization to continued employment rather than performance metrics. From a financial perspective, the filing communicates grant size, strike, and vesting but provides no valuation, tax treatment, or acceleration provisions.
TL;DR Grants are employment-contingent with multi-year vesting; governance implications are routine and disclosure is complete for a Form 4.
The filing clearly states the nature and schedule of the awards: 300,000 stock options and 150,000 RSUs, both held directly. Each RSU equals a contingent right to one share. Vesting requires continued employment and is staggered (1/3 after one year, remaining in eight quarterly installments). The option term shown (to 08/06/2035) indicates a ten-year contractual horizon from grant date. The Form 4 provides the governance-relevant facts investors need regarding timing and ownership; no accelerated vesting or other special conditions are disclosed in the explanation section.
Corleen M. Roche, Chief Financial Officer di Iovance Biotherapeutics (IOVA), ha segnalato attribuzioni di capitale datate 08/06/2025. Il Form 4 indica una concessione di 300,000 opzioni su azioni con prezzo di esercizio di $2.58 e data di scadenza 08/06/2035, e 150,000 unità azionarie vincolate (RSU), ciascuna rappresentante un diritto condizionato a una azione ordinaria. Entrambe le assegnazioni sono detenute direttamente dopo le operazioni riportate. Le assegnazioni maturano solo se la dichiarante rimane impiegata: un terzo matura al primo anniversario della concessione e i restanti due terzi maturano in otto rate trimestrali uguali nei due anni successivi. Il modulo è firmato da Corleen Roche il 08/08/2025.
Corleen M. Roche, directora financiera (Chief Financial Officer) de Iovance Biotherapeutics (IOVA), informó adjudicaciones de capital fechadas 08/06/2025. El Form 4 revela una concesión de 300,000 opciones sobre acciones con un precio de ejercicio de $2.58 y fecha de vencimiento 08/06/2035, y 150,000 unidades de acciones restringidas (RSU), cada una representando un derecho condicional a una acción común. Ambas adjudicaciones se mantienen en propiedad directa tras las transacciones reportadas. Las adjudicaciones solo se consolidan si la persona informante permanece empleada: un tercio se consolida en el primer aniversario de la concesión y los restantes dos tercios se consolidan en ocho cuotas trimestrales iguales durante los dos años siguientes. El formulario está firmado por Corleen Roche el 08/08/2025.
Iovance Biotherapeutics (IOVA)의 최고재무책임자(CFO) Corleen M. Roche가 08/06/2025자 자본 보상 내역을 보고했습니다. Form 4는 행사가 $2.58인 스톡옵션 300,000주의 부여와 만기일 08/06/2035, 그리고 제한부주식단위(RSU) 150,000주(각각 보통주 1주에 대한 조건부 권리)를 공개합니다. 두 보상 모두 보고된 거래 이후 직접 보유됩니다. 보상은 보고인이 계속 고용된 경우에만 확정됩니다: 1/3은 부여일로부터 1년 되는 날에 확정되고, 나머지 2/3은 이후 2년 동안 8회의 동일한 분기별 할부로 확정됩니다. 양식은 08/08/2025에 Corleen Roche가 서명했습니다.
Corleen M. Roche, directrice financière (Chief Financial Officer) d'Iovance Biotherapeutics (IOVA), a déclaré des attributions de capital datées 08/06/2025. Le Form 4 indique une attribution de 300,000 options sur actions avec un prix d'exercice de $2.58 et une date d'expiration au 08/06/2035, et 150,000 unités d'actions restreintes (RSU), chacune représentant un droit conditionnel à une action ordinaire. Les deux attributions sont détenues directement après les opérations déclarées. Les attributions ne deviennent acquises que si la personne déclarée reste employée : un tiers devient acquis à l'anniversaire d'un an de l'attribution et les deux tiers restants deviennent acquis en huit versements trimestriels égaux au cours des deux années suivantes. Le formulaire est signé par Corleen Roche le 08/08/2025.
Corleen M. Roche, Chief Financial Officer von Iovance Biotherapeutics (IOVA), meldete Aktienzuteilungen datiert 08/06/2025. Das Form 4 gibt eine Gewährung von 300,000 Aktienoptionen mit einem Ausübungspreis von $2.58 und einem Verfallsdatum am 08/06/2035 sowie 150,000 Restricted Stock Units (RSUs) an, wobei jede eine bedingte Anspruchsberechtigung auf eine Stammaktie darstellt. Beide Zuteilungen werden nach den gemeldeten Transaktionen direkt gehalten. Die Zuteilungen erfolgen nur, falls die meldepflichtige Person weiter beschäftigt bleibt: ein Drittel wird am einjährigen Jahrestag der Gewährung fällig und die verbleibenden zwei Drittel in acht gleichen vierteljährlichen Tranchen über die folgenden zwei Jahre. Das Formular ist am 08/08/2025 von Corleen Roche unterzeichnet.
FAQ
What did Corleen Roche report on the IOVA Form 4?
When do the options and RSUs vest for IOVA CFO Corleen Roche?
Do the RSUs convert to shares for Iovance (IOVA)?
What is the option term and exercise price reported on the Form 4?
When was the Form 4 signed by the reporting person?
